A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

NCT06192576 · clinicaltrials.gov ↗

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Niemann-Pick Diseases
Acid Sphingomyelinase Deficiency

Interventions

DRUG: Olipudase alfa

Sponsor

Sanofi

Collaborators

[object Object]